Welcome to our dedicated page for Dicerna news (Ticker: DRNA), a resource for investors and traders seeking the latest updates and insights on Dicerna stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dicerna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dicerna's position in the market.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced positive interim results from its ongoing PHYOX™3 trial for nedosiran, an investigational treatment for primary hyperoxaluria (PH). Out of 13 participants, 92% achieved normal or near-normal urinary oxalate excretion after six months. Specifically, 100% of PH1 participants and 67% of PH2 participants reached the desired urinary levels. The trial demonstrated a mean reduction in urinary oxalate excretion of 70.9%. Nedosiran was well tolerated, with no serious safety concerns arising.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced that Douglas M. Fambrough, Ph.D., CEO, will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on October 20, 2020, at 9:30 a.m. ET. A live audio webcast will be available on the Company's website, with an archived replay following the event.
Dicerna specializes in RNA interference (RNAi) therapeutics, aiming to silence disease-causing genes. The company is engaged in over 20 active clinical and preclinical programs targeting various diseases in collaboration with major pharmaceutical firms.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) will showcase clinical data on its investigational drug, nedosiran, aimed at treating primary hyperoxaluria (PH) during the American Society of Nephrology Kidney Week from Oct. 22-25, 2020. Notably, two poster presentations will focus on the long-term effects of nedosiran and a claims analysis of the disease's economic burden. As the only RNAi therapy in development for PH types 1, 2, and 3, nedosiran has the potential to significantly impact treatment options for patients suffering from this rare genetic disorder.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced the approval of inducement grants comprising 288,525 stock options and 65,675 restricted stock units (RSUs) for eight new employees, effective October 1, 2020. Shreeram Aradhye, M.D., and Ling Zeng received significant portions of these grants. The stock options have an exercise price of $18.69 and vest over four years, while RSUs vest 25% annually. The grants comply with Nasdaq Rule 5635(c)(4), aimed at attracting and retaining new talent to strengthen the company's RNAi therapeutic development.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced that CEO Douglas M. Fambrough, Ph.D., will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:30 p.m. ET. A live audio webcast will be available on the company's website, with an archived replay post-event. Dicerna focuses on developing RNAi therapeutics to silence disease-causing genes, leveraging its GalXC™ platform, and collaborates with leading pharmaceutical companies on over 20 active programs targeting various diseases.